ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2371

Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis

Salem Almaani1, Huijuan Song2, Stacy Ardoin3, Lynn Fussner2 and Brad Rovin2, 1Ohio State University Medical Center, Columbus, OH, 2Ohio State University, Columbus, OH, 3Nationwide Children's Hospital, Columbus, OH

Meeting: ACR Convergence 2023

Keywords: ANCA associated vasculitis, Biomarkers, cytokines

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 14, 2023

Title: (2370–2386) Vasculitis – ANCA-Associated Poster III: Biomarkers & Renal Outcomes

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: ANCA-associated vasculitis (AAV) is a multisystem autoimmune disease that often affects the kidneys. It is unclear why some patients with AAV have kidney involvement while others do not. To investigate the mechanisms underlying these phenotypes, this study examined plasma and urine cytokine profiles in patients with active renal and non-renal AAV (AAGN and NR-AAV, respectively), and healthy controls (HC).

Methods: Levels of 200 cytokines were measured in the plasma and urine of 6 patients with active AAGN, 9 patients with NR-AAV, and 3 HC using a human cytokine array. Urine cytokine levels were corrected to urine creatinine and an analyte-to-creatinine ratio was utilized for analysis. Levels in the three groups were compared using ANOVA. Analytes with false discovery rate (FDR)-corrected p-values < 0.05 were further compared using Tukey HSD post-hoc test.

Results: Patient Characteristics are depicted in Table 1. Most cytokines measured were similar between HC and NR-AAV patients. Compared to patients with NR-AAV, patients with AAGN had higher levels of plasma and urine cytokines that are involved in involved in Th17 signaling (IL-17A, IL-17F, IL-17R, IL-23, IL-6), Th1 response (IL-12, GM-CSF, IFNg, TNFa), chemotaxis (especially for T-cells, monocytes, and dendritic cells – eotaxin-2, I-TAC, Lymphotactin, MCP-3, MIP-3a, CCL23), B and T-cell crosstalk (B7-1, CD40, CD40L), and angiogenesis (VEGFR1, FLT4, VEGF-C, VEGF-D, SDF1a) (Figure 1).

Conclusion: Compared to NR-AAV, AAGN is associated with an increase in plasma and urine levels of many pro-inflammatory cytokines. T-cell differentiation, signaling, and crosstalk seem to be the most prominent molecular processes that are active in patients with AAGN. These data suggest a prominent role of T-cells in AAGN which have the potential of being leveraged therapeutically.

Supporting image 1

Table 1. Patient Characteristics

Supporting image 2

Figure 1. Difference in urine (a) and plasma (b) levels of cytokines in patients with active renal and non-renal vasculitis.


Disclosures: S. Almaani: Amgen, 2, Aurinia, 2, Chemocentryx, 2, Kezar, 2, Otsuka, 2; H. Song: None; S. Ardoin: None; L. Fussner: Amgen, 2; B. Rovin: AstraZeneca, 2, 5, Aurinia, 2, 5, Biogen, 2, F. Hoffmann-La Roche Ltd, 2, Genentech, 2, GlaxoSmithKlein(GSK), 2, Novartis, 2.

To cite this abstract in AMA style:

Almaani S, Song H, Ardoin S, Fussner L, Rovin B. Plasma and Urine Cytokine Profiles in Active ANCA-Associated Vasculitis [abstract]. Arthritis Rheumatol. 2023; 75 (suppl 9). https://acrabstracts.org/abstract/plasma-and-urine-cytokine-profiles-in-active-anca-associated-vasculitis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to ACR Convergence 2023

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-and-urine-cytokine-profiles-in-active-anca-associated-vasculitis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology